FDA kwadoro ibrutinib maka ọgwụgwọ ọrịa na-adịghị ala ala graft-versus-host (cGVHD) na ụmụaka.

N'August 24, 2022, US Food and Drug Administration (FDA) kwadoro ibrutinib maka ọgwụgwọ ụmụaka ndị ọrịa ụmụaka karịrị otu afọ nwere ọrịa graft-versus-host (cGVHD) na-anata Mgbe ọdịda nke 1- ma ọ bụ multi-line. usoro ọgwụgwọ .Ngosipụta akwadoro bụ nke kachasị maka ndị ọrịa ụmụaka, yana ọnụ ọgụgụ nzaghachi zuru oke nke 60% n'izu 25, na usoro ọgwụ ahụ gụnyere capsules, mbadamba na nkwusioru ọnụ.

Ibrutinib, onye na-egbochi BTK mebere site na Pharmacyclics/Johnson & Johnson, bụ kinase inhibitor nke akwadoro na mbụ maka ọgwụgwọ ọrịa leukemia lymphocytic na-adịghị ala ala yana lymphoma cell na ọrịa ndị ọzọ.

Suntech na-elekwasị anya na mmepe na mmepụta nke intermediates ọgwụ na API site na iji teknụzụ ndụ ndụ.Ka ọ dị ugbu a, ụlọ ọrụ anyị emepụtala ngwaahịa atọ nke ibrutinib gụnyere C AS: 143900-44-1, C AS: 330792-70-6, C AS: 330786-24-8, nke a na-ere ahịa na mmepụta ụlọ ọrụ GMP. .N'ime ha, etiti nke C AS: 143900-44-1 na-emepụta site na nkà na ụzụ chemical-enzymatic , nke nwere uru nke nchebe gburugburu ebe obibi ndụ ndụ, ọnụ ala dị ala na àgwà dị elu.Nabata ka ị kpọtụrụ na imekọ ihe ọnụ!